Cybin bags breakthrough tag for psychedelic depression drug
pharmaphorum
MARCH 14, 2024
Cybin files a $150m placement on the back of new clinical data with its psychedelic drug CYB003 for depression and an FDA breakthrough designation.
tag depression 
103 
FDA Approval of First Rapid-Acting Oral Depression Drug + Approval of $2.8 Million Gene Therapy for Rare Blood Disorder – Xtalks Life Science Podcast Ep. 75
XTalks
AUGUST 31, 2022
In this episode, Ayesha discussed the FDA approval of Axsome Therapeutics’ rapid-acting oral treatment Auvelity for the treatment of major depressive disorder (MDD). The approval makes Auvelity the first and only rapid-acting oral medication for depression, and the first and only oral NMDA receptor antagonist approved for MDD.
Join 32,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Jolly Good/Teijin Pharma develop VR digital therapeutics for depression
pharmaphorum
APRIL 26, 2021
Technology firm Jolly Good and Teijin Pharma have begun a partnership to develop virtual reality digital therapeutics (VR DTx) for major depressive disorder. However Nokia famously ran into trouble when it tried to develop VR products for digital health and its OZO camera failed to catch on, mainly because of a high $60,000 price tag.
Axsome bounces back as FDA clears depression drug
pharmaphorum
AUGUST 21, 2022
Shares in Axsome Therapeutics have rocketed on FDA approval of its depression therapy Auvelity (formerly AXS-05) – a year after its approval was held up by the regulator. The post Axsome bounces back as FDA clears depression drug appeared first on. Photo by Sydney Sims on Unsplash.
J&J builds case for antidepressant Spravato with head-to-head trial
pharmaphorum
NOVEMBER 24, 2022
Johnson & Johnson’s Spravato therapy for treatment-resistant depression (TRD) hasn’t made the impact the company hoped for in the market, and it is looking to new clinical results to accelerate its take-up. Both drugs were given on top of standard antidepressants to patients wo had failed a least two earlier treatments.
Blue Note leukaemia DTx gets FDA breakthrough tag
pharmaphorum
JANUARY 11, 2022
The DTx, called BNT200, is described as a first-of-its-kind DTx to treat anxiety and depression in adults with acute myeloid leukaemia (AML) who are hospitalised for a regimen of high-intensity induction chemotherapy. The post Blue Note leukaemia DTx gets FDA breakthrough tag appeared first on.
Grand Rounds September 23, 2022: Effect Of An Intensive Nurse Home Visiting Program On Adverse Birth Outcomes In A Medicaid-Eligible Population (Margaret McConnell, PhD)
Rethinking Clinical Trials
SEPTEMBER 30, 2022
The types of services NFP nurses provide include health assessments, such as prenatal health assessment, monitoring weight and blood pressure; screening for depression, anxiety, intimate partner violence; referrals to health care providers and community resources; educational content; and psychosocial support. pctGR, @Collaboratory1.
Let's personalize your content